The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).
The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...
The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...
Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
The health secretary is planning to remove members of a panel that recommends vaccines if he sees conflicts of interest.
18, 2025 – The FDA has approved a new 5-in-1 shot to ... Sold as Penmenvy, it combines the active ingredients of two previously approved vaccines, offering better protection with fewer shots ...
Over the last 30 days, 151 flocks have been confirmed to have avian flu, affecting more than 23 million birds, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results